Juvenile dermatomyositis: Difference between revisions
CSV import |
CSV import |
||
| Line 18: | Line 18: | ||
}} | }} | ||
{{DISPLAYTITLE:Juvenile Dermatomyositis}} | {{DISPLAYTITLE:Juvenile Dermatomyositis}} | ||
[[File:Dermatomyositis13.jpg|left|thumb|Characteristic rash of juvenile dermatomyositis]] | [[File:Dermatomyositis13.jpg|left|thumb|Characteristic rash of juvenile dermatomyositis]] | ||
'''Juvenile dermatomyositis''' (JDM) is a rare and chronic inflammatory disease that affects the skin and muscles. It is a subtype of [[dermatomyositis]] that occurs in children, typically between the ages of 5 and 15. JDM is characterized by muscle weakness and a distinctive skin rash. | '''Juvenile dermatomyositis''' (JDM) is a rare and chronic inflammatory disease that affects the skin and muscles. It is a subtype of [[dermatomyositis]] that occurs in children, typically between the ages of 5 and 15. JDM is characterized by muscle weakness and a distinctive skin rash. | ||
Latest revision as of 22:11, 8 April 2025

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Juvenile dermatomyositis | |
|---|---|
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Muscle weakness, skin rash, fatigue |
| Complications | Calcinosis, dysphagia, pulmonary disease |
| Onset | Typically between ages 5 and 10 |
| Duration | Chronic |
| Types | N/A |
| Causes | Unknown, possibly autoimmune |
| Risks | Genetic predisposition, environmental factors |
| Diagnosis | Clinical examination, muscle biopsy, MRI, blood tests |
| Differential diagnosis | Polymyositis, lupus erythematosus, scleroderma |
| Prevention | N/A |
| Treatment | Corticosteroids, immunosuppressants, physical therapy |
| Medication | N/A |
| Prognosis | Variable, can be managed with treatment |
| Frequency | Rare, 2-4 cases per million children per year |
| Deaths | N/A |
Juvenile dermatomyositis (JDM) is a rare and chronic inflammatory disease that affects the skin and muscles. It is a subtype of dermatomyositis that occurs in children, typically between the ages of 5 and 15. JDM is characterized by muscle weakness and a distinctive skin rash.
Pathophysiology[edit]
The exact cause of juvenile dermatomyositis is unknown, but it is believed to be an autoimmune disease. In JDM, the body's immune system mistakenly attacks its own muscle fibers and skin tissues. This leads to inflammation and damage, resulting in the symptoms associated with the disease.
Symptoms[edit]
The primary symptoms of juvenile dermatomyositis include:
- Muscle weakness: This usually affects the proximal muscles, such as those in the hips, thighs, shoulders, and neck.
- Skin rash: A distinctive rash, often referred to as a heliotrope rash, appears on the eyelids and cheeks. Gottron's papules, which are red or purple bumps, may appear on the knuckles.
- Fatigue: Children with JDM often experience significant fatigue and may have difficulty performing daily activities.
- Joint pain: Some children may experience joint pain or arthritis.
Diagnosis[edit]
Diagnosing juvenile dermatomyositis involves a combination of clinical evaluation, laboratory tests, and imaging studies. Common diagnostic tools include:
- Blood tests: Elevated levels of muscle enzymes such as creatine kinase (CK) and aldolase can indicate muscle damage.
- Electromyography (EMG): This test measures the electrical activity of muscles and can help identify muscle inflammation.
- Muscle biopsy: A small sample of muscle tissue may be taken to look for signs of inflammation and damage.
- MRI: Magnetic resonance imaging can help visualize muscle inflammation.
Treatment[edit]
The treatment of juvenile dermatomyositis focuses on reducing inflammation, improving muscle strength, and preventing complications. Common treatments include:
- Corticosteroids: Medications such as prednisone are often used to reduce inflammation.
- Immunosuppressive drugs: Medications like methotrexate or azathioprine may be used to suppress the immune system.
- Physical therapy: Exercise and physical therapy are important to maintain muscle strength and flexibility.
- Sun protection: Since sunlight can exacerbate the skin rash, sun protection measures are recommended.
Prognosis[edit]
The prognosis for children with juvenile dermatomyositis varies. With early diagnosis and appropriate treatment, many children can achieve remission and lead normal lives. However, some may experience chronic symptoms or complications such as calcinosis, where calcium deposits form in the skin or muscles.